TMC-310911

DB15623InvestigationalSmall molecule

TMC-310911 (also known as ASC-09) is a novel investigational protease inhibitor (PI) that is structurally similar to the currently available darunavir. It is being investigated for use in HIV-1 infections.... TMC-310911 has shown marked activity against a variety of HIV-1 strains, including multi-PI-resistant strains, and may be less likely to generate resistance, making it a potentially desirable therapy for both treatment-naive and PI-experienced patients.

Formula / weight: C₃₈H₅₃N₅O₇S₂ · 755.987 g/mol (avg)
Code names: ASC-09 · TMC-310911

Resolves to

Compound

UNII0151W500HPCAS1000287-05-7ChEMBLCHEMBL4756129

Structure

InChIKeyJQUNFHFWXCXPRK-AMMMHQJVSA-NSMILES

[H][C@@]12CCO[C@]1([H])OC[C@@H]2OC(=O)N[C@@H](CC1=CC=CC=C1)[C@H](O)CN(CC(C)C)S(=O)(=O)C1=CC=C2N=C(NC3CCN(CC3)C3CCCC3)SC2=C1

Targets

P03369gag-polP03366gag-pol

What you can answer from here — as of September 21, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

67Drug interactionsStructured to mechanism, not free text

3Clinical trialsPhase, status and sponsor resolved per trial

9+ReferencesStructured and connected to the statements they support

Which drugs share a target with TMC-310911, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account